Valuation Outlook

The company’s market capitalization is $30.56 billion. Following the earnings release, the stock rose 8.9 % to $205.04. Analyst valuation models show a 26.8 % discount to a DCF intrinsic value of $253.87 per share, while a P/E‑based fair value estimate ranges from $232.80 to $380.00. Competitive pressures have led to temporary losses, but Veeva’s deep life‑sciences expertise and AI product pipeline are cited as mitigators, with investors noting both growth potential and near‑term risks such as macro uncertainty and challenges in the EDC market.